Phaseline

Companies › Immutep S.A.S.

Immutep S.A.S.: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 1 Phase 3, 1 Phase 2, 1 Phase 1; Oncology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
eftilagimod alfa
Lymphocyte activation gene 3 protein vaccine antigen
LAG3Phase 3Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC); Neoadjuvant; Solid TumorsJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03252938eftilagimod alfaPhase 1Solid TumorsOncologySep 2026
NCT06128863eftilagimod alfaPhase 2NeoadjuvantOncologyApr 2027
NCT06726265eftilagimod alfaPhase 3Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)OncologyJun 2027

From the company's SEC filings

Cash and short-term investments of 130m AUD on 2025-06-30; operating cash outflow about 62m AUD a year; runway about 25 months at that burn, to Jul 2027; 2 of 2 coming phase 2-3 readouts fall inside that runway

Targets

LAG3 (1)

Companies with the same targets

Regeneron Pharmaceuticals Merck & Co. (MSD) Bristol-Myers Squibb Roche Akeso Shenyang Sunshine Pharmaceutical Shanghai Henlius Biotech

Companies built like this

ADC Therapeutics Candel Therapeutics Actinium Pharmaceuticals Maia Biotechnology K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.